Urvi A. Shah

4.2k total citations
94 papers, 1.6k citations indexed

About

Urvi A. Shah is a scholar working on Hematology, Oncology and Molecular Biology. According to data from OpenAlex, Urvi A. Shah has authored 94 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 36 papers in Hematology, 25 papers in Oncology and 19 papers in Molecular Biology. Recurrent topics in Urvi A. Shah's work include Multiple Myeloma Research and Treatments (35 papers), Protein Degradation and Inhibitors (9 papers) and CAR-T cell therapy research (7 papers). Urvi A. Shah is often cited by papers focused on Multiple Myeloma Research and Treatments (35 papers), Protein Degradation and Inhibitors (9 papers) and CAR-T cell therapy research (7 papers). Urvi A. Shah collaborates with scholars based in United States, United Kingdom and India. Urvi A. Shah's co-authors include Sham Mailankody, Wendy Atkin, Kate Wooldrage, Ines Kralj‐Hans, Stephen W. Duffy, Amanda J. Cross, Murali Janakiram, Xingxing Zang, Weifeng Liu and Aimin Zhao and has published in prestigious journals such as The Lancet, JAMA and Circulation.

In The Last Decade

Urvi A. Shah

81 papers receiving 1.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Urvi A. Shah United States 18 787 349 298 298 233 94 1.6k
Ippokratis Messaritakis Greece 23 634 0.8× 243 0.7× 375 1.3× 131 0.4× 78 0.3× 62 1.5k
Tsiporah B. Shore United States 27 919 1.2× 252 0.7× 369 1.2× 870 2.9× 114 0.5× 152 2.3k
Marcus Gorschlüter Germany 20 910 1.2× 250 0.7× 341 1.1× 230 0.8× 190 0.8× 44 1.6k
Ali Ünal Türkiye 23 369 0.5× 135 0.4× 242 0.8× 835 2.8× 292 1.3× 125 2.1k
Aaron S. Rosenberg United States 24 438 0.6× 116 0.3× 468 1.6× 458 1.5× 229 1.0× 87 1.9k
Hugo Sousa Portugal 28 653 0.8× 117 0.3× 527 1.8× 93 0.3× 222 1.0× 83 1.8k
Jaime Sanz Spain 27 791 1.0× 211 0.6× 278 0.9× 1.6k 5.5× 178 0.8× 191 2.5k
Parastoo B. Dahi United States 18 930 1.2× 117 0.3× 518 1.7× 494 1.7× 51 0.2× 111 1.7k
Shigesaburo Miyakoshi Japan 26 596 0.8× 130 0.4× 141 0.5× 982 3.3× 148 0.6× 90 1.7k
Donna Salzman United States 18 368 0.5× 171 0.5× 103 0.3× 358 1.2× 133 0.6× 57 1.2k

Countries citing papers authored by Urvi A. Shah

Since Specialization
Citations

This map shows the geographic impact of Urvi A. Shah's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Urvi A. Shah with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Urvi A. Shah more than expected).

Fields of papers citing papers by Urvi A. Shah

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Urvi A. Shah. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Urvi A. Shah. The network helps show where Urvi A. Shah may publish in the future.

Co-authorship network of co-authors of Urvi A. Shah

This figure shows the co-authorship network connecting the top 25 collaborators of Urvi A. Shah. A scholar is included among the top collaborators of Urvi A. Shah based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Urvi A. Shah. Urvi A. Shah is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Kassam, Shireen, et al.. (2025). Food for Thought: Addressing a Research Gap for Dietary Trials in Hematologic Malignancies. Blood Cancer Discovery. 6(5). 406–411. 1 indexed citations
2.
Abdel‐Wahab, Omar, et al.. (2025). The Link between Modifiable Risk Factors and Myeloid Disorders—From Plate to Pathogenesis. Blood Cancer Discovery. 7(1). 31–40.
3.
Tan, Carlyn, Andriy Derkach, Kylee Maclachlan, et al.. (2024). Real-world schedule de-escalation of teclistamab in patients with relapsed/refractory multiple myeloma.. Journal of Clinical Oncology. 42(16_suppl). 7536–7536. 8 indexed citations
4.
Shah, Urvi A., et al.. (2023). Dietary and microbiome evidence in multiple myeloma and other plasma cell disorders. Leukemia. 37(5). 964–980. 17 indexed citations
5.
Derkach, Andriy, et al.. (2023). Pre-diagnosis dietary patterns and risk of multiple myeloma in the NIH-AARP diet and health study. Leukemia. 38(2). 438–441. 4 indexed citations
6.
Derkach, Andriy, Billel Gasmi, Theodora Anagnostou, et al.. (2023). T-Cell Exhaustion Signature Predicts Early Relapse after Autologous Stem Cell Transplant for Multiple Myeloma: BMT CTN 0702 Secondary Immune Analysis. Blood. 142(Supplement 1). 3326–3326. 1 indexed citations
7.
Hillengaß, Jens, Li Tang, Alexander M. Lesokhin, et al.. (2023). Dietary risk factors for monoclonal gammopathy of undetermined significance in a racially diverse population. Blood Advances. 8(3). 538–548. 4 indexed citations
8.
Firestone, Ross, Andriy Derkach, Kylee Maclachlan, et al.. (2023). P-486 Clinical significance of baseline body mass index and its trajectory during triplet induction therapy in newly diagnosed multiple myeloma. Clinical Lymphoma Myeloma & Leukemia. 23. S307–S308. 1 indexed citations
9.
Firestone, Ross, Carlyn Tan, Malin Hultcrantz, et al.. (2023). Evaluating the efficacy of commercial teclistamab in relapsed refractory multiple myeloma patients with prior exposure to anti-BCMA therapies.. Journal of Clinical Oncology. 41(16_suppl). 8049–8049. 7 indexed citations
10.
Korde, Neha, Benjamin Diamond, Hani Hassoun, et al.. (2022). Maintenance Therapy Cessation for Sustained MRD Negative Multiple Myeloma Patients. Blood. 140(Supplement 1). 2397–2398. 3 indexed citations
11.
Korde, Neha, Malin Hultcrantz, Hani Hassoun, et al.. (2022). Clinical efficacy of daratumumab (DARA)-based second line therapy after DARA-containing and DARA-free induction therapies in multiple myeloma: A single center experience.. Journal of Clinical Oncology. 40(16_suppl). e20005–e20005. 1 indexed citations
12.
13.
Tariq, Syed Maaz, et al.. (2021). A comprehensive review of the impact of obesity on plasma cell disorders. Leukemia. 36(2). 301–314. 17 indexed citations
14.
Shah, Urvi A., et al.. (2020). Efficacy of platelet-rich plasma and concentrated growth factor in treating androgenetic alopecia - A retrospective study. Annals of Maxillofacial Surgery. 10(2). 409–409. 14 indexed citations
15.
Shah, Urvi A. & Sham Mailankody. (2020). CAR T and CAR NK cells in multiple myeloma: Expanding the targets. Best Practice & Research Clinical Haematology. 33(1). 101141–101141. 37 indexed citations
16.
Chung, Elaine Y., Urvi A. Shah, Yongqiang Wei, et al.. (2019). PAK Kinase Inhibition Has Therapeutic Activity in Novel Preclinical Models of Adult T-Cell Leukemia/Lymphoma. Clinical Cancer Research. 25(12). 3589–3601. 17 indexed citations
17.
Shah, Urvi A., Beamon Agarwal, Aditi Shastri, et al.. (2018). Sinusoidal Obstruction Syndrome (SOS) in Multiple Myeloma with Renal Failure. Case Reports in Oncological Medicine. 2018. 1–6.
18.
Baral, Ratna, et al.. (2016). A Study of Prevalence of Intestinal Protozoan Infections and Associated Risk Factors among the School Children of Biratnagar Submetropolitan, Eastern Region of Nepal. Asian Pacific Journal of Health Sciences. 3(1). 181–197. 6 indexed citations
19.
Karásek, David, Urvi A. Shah, Zdeněk Fryšák, Constantine A. Stratakis, & Karel Pacák. (2012). An update on the genetics of pheochromocytoma. Journal of Human Hypertension. 27(3). 141–147. 36 indexed citations
20.
Chey, William D., Charles F. Barish, Dennis Riff, et al.. (1998). The Chemtrak Hp Chek Fingerstick Whole Blood Serology Test for the Detection of Helicobacter pylori Infection. The American Journal of Gastroenterology. 93(1). 16–19. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ippokratis Messaritakis Breakdown of academic impact, for papers by Tsiporah B. Shore Breakdown of academic impact, for papers by Marcus Gorschlüter Breakdown of academic impact, for papers by Ali Ünal Breakdown of academic impact, for papers by Aaron S. Rosenberg Breakdown of academic impact, for papers by Hugo Sousa Breakdown of academic impact, for papers by Jaime Sanz Breakdown of academic impact, for papers by Parastoo B. Dahi Breakdown of academic impact, for papers by Shigesaburo Miyakoshi Breakdown of academic impact, for papers by Donna Salzman
Rankless by CCL
2026